INSUBCONTINENT EXCLUSIVE:
Codagenix, a company developing vaccines and viral therapies for illnesses ranging from the flu and respiratory viruses to dengue fever,
participation from Euclidean Capital and Topspin Partners .Codagenix will use the funds to support clinical development of its general flu
replacing more virulent pathogens with milder strains.Codagenix said it will use the new financing to bring its RSV and flu vaccines through
Phase 1 trials and move its oncology program for a breast cancer treatment into Phase 1 clinical trials
potential to develop optimized, more affordable versions of existing vaccines, Codagenix is poised to solve persistent public health
Rockman, managing partner at Adjuvant Capital
Brook University in New York in 2012, Codagenix has received backing from government institutions like the National Institute of Health, the
Department of Agriculture and the United States Army for its dengue fever, flu, swine flu, RSV and foot and mouth disease virus vaccines.In
all, the company has raised $38 million from private nonprofits and venture capital investors, and $11 million in federal funding.
